Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Abstract here

Abstract here

Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…

DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each…

The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected…

DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each…

DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each…

DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each…

DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each…

The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span…

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…